| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2023 | 492.11% | HC Wainwright & Co. | $7 → $4.5 | Maintains | Buy |
| 07/19/2023 | 821.05% | HC Wainwright & Co. | → $7 | Reiterates | Buy → Buy |
| 06/30/2023 | 557.89% | EF Hutton | → $5 | Reiterates | Buy → Buy |
| 06/30/2023 | 821.05% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 06/26/2023 | 952.63% | HC Wainwright & Co. | → $8 | Reiterates | Buy → Buy |
| 06/20/2023 | 294.74% | Benchmark | → $3 | Reiterates | Speculative Buy → Speculative Buy |
| 05/17/2023 | 952.63% | HC Wainwright & Co. | → $8 | Reiterates | Buy → Buy |
| 05/17/2023 | 557.89% | EF Hutton | → $5 | Reiterates | Buy → Buy |
| 04/21/2023 | 294.74% | Benchmark | $13 → $3 | Maintains | Speculative Buy |
| 04/03/2023 | 952.63% | HC Wainwright & Co. | → $8 | Reiterates | → Buy |
| 03/31/2023 | 3057.89% | EF Hutton | → $24 | Reiterates | → Buy |
| 03/09/2023 | 557.89% | EF Hutton | → $5 | Initiates Coverage On | → Buy |
| 03/09/2023 | 952.63% | HC Wainwright & Co. | → $8 | Reiterates | → Buy |
| 03/09/2023 | 689.47% | Maxim Group | $3 → $6 | Maintains | Buy |
| 11/28/2022 | 952.63% | HC Wainwright & Co. | $9 → $8 | Maintains | Buy |
| 06/08/2022 | 1084.21% | HC Wainwright & Co. | → $9 | Initiates Coverage On | → Buy |
| 03/16/2022 | 294.74% | Maxim Group | → $3 | Initiates Coverage On | → Buy |
| 08/09/2021 | 1676.32% | Roth Capital | → $13.5 | Initiates Coverage On | → Buy |
What is the target price for Unicycive Therapeutics (UNCY)?
The latest price target for Unicycive Therapeutics (NASDAQ: UNCY) was reported by HC Wainwright & Co. on August 16, 2023. The analyst firm set a price target for $4.50 expecting UNCY to rise to within 12 months (a possible 492.11% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Unicycive Therapeutics (UNCY)?
The latest analyst rating for Unicycive Therapeutics (NASDAQ: UNCY) was provided by HC Wainwright & Co., and Unicycive Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for Unicycive Therapeutics (UNCY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Unicycive Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Unicycive Therapeutics was filed on August 16, 2023 so you should expect the next rating to be made available sometime around August 16, 2024.
Is the Analyst Rating Unicycive Therapeutics (UNCY) correct?
While ratings are subjective and will change, the latest Unicycive Therapeutics (UNCY) rating was a maintained with a price target of $7.00 to $4.50. The current price Unicycive Therapeutics (UNCY) is trading at is $0.76, which is out of the analyst's predicted range.